Citius Pharmaceuticals (CTXR) Other Accumulated Expenses (2020 - 2023)

Citius Pharmaceuticals (CTXR) has 4 years of Other Accumulated Expenses data on file, last reported at $4.1 million in Q3 2023.

• Quarterly Other Accumulated Expenses rose 11.14% year-over-year to $4.1 million in Q3 2023, while the trailing twelve-month figure through Sep 2023 was $4.1 million (up 11.14% YoY) and the FY2023 annual result came in at $4.1 million, up 11.14% from the prior year.
• Other Accumulated Expenses grew to $4.1 million in Q3 2023, from $3.7 million in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $4.1 million in Q3 2023 to a low of $1.5 million in Q3 2020.
• A 4-year average of $3.0 million and a median of $3.1 million in 2021 frame the typical range for Other Accumulated Expenses.
• Annual changes were most pronounced in 2021 — Other Accumulated Expenses surged 70.14% — and 2023, when it climbed 11.14%.
• Tracing CTXR's Other Accumulated Expenses over 4 years: stood at $1.5 million in 2020, then surged by 70.14% to $2.6 million in 2021, then surged by 43.88% to $3.7 million in 2022, then advanced by 11.14% to $4.1 million in 2023.
• The last three Other Accumulated Expenses figures came in at $4.1 million (Q3 2023), $3.7 million (Q3 2022), and $2.6 million (Q3 2021), per Business Quant data.